XCUR earnings analysis
What we found in XCUR's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Exicure remains a pre-revenue, single-segment biotechnology company, reporting $0 revenue and diluted EPS of $(0.18) for Q2 2026; the quarterly loss improved from $(0.41) a year earlier primarily because of sharply lower R&D and G&A spending. Cash fell to $1.717 million from $3.746 million at year-end, with $2.029 million of operating cash burn during the first six months, and management states that current liquidity is insufficient for the next 12 months. The filing reiterates substantial doubt about going-concern status, highlights a Nasdaq stockholders’ equity deficiency, and provides no quantitative earnings or revenue guidance.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- No Revenue in Single Operating Segment
- Revenue remained $0 for the quarter and six-month period, unchanged from the comparable 2025 periods. The Company continues to operate as a single Biotechnology segment with no reported revenue.
- Quarterly Loss Improved
- Diluted EPS was $(0.18), improving from $(0.41) in Q2 2025 and $(0.29) in Q1 2026. Net loss was $1.121 million versus $2.621 million in Q2 2025, a $1.500 million or 57% improvement.
- Operating Costs Were Reduced
- Six-month R&D expense declined to $1.743 million, down $1.257 million or 72% year over year, while G&A expense fell to $2.180 million from $3.731 million, down $1.551 million or 42%. Management attributed the reductions to deferred spending, lower headcount and reduced professional-services costs.
- Capital Spending Was Minimal
- Net cash used in operating activities was $2.029 million for the six months ended June 30, 2026, and investing cash flow was $0, with no current-year investing activities. Cash and equivalents declined to $1.717 million from $3.746 million at December 31, 2025.
- Milestone Obligation Shifted to Equity
- GPCR USA completed its Phase 2 clinical trial in January 2026. The first milestone payment of $1.000 million became payable in Q2 2026, and the amended payment terms are expected to be satisfied through issuance of Company common shares rather than cash.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Severe Liquidity and Going-Concern Risk
- Management states that the $1.717 million cash balance will not be sufficient to fund planned operations for at least the 12-month period following issuance. The filing concludes that substantial doubt exists regarding going-concern status and warns that the Company may seek bankruptcy protection or cease operations.
- Nasdaq Equity Deficiency
- Nasdaq notified the Company that stockholders’ equity was $2.098 million, below the $2.5 million minimum requirement. The Company submitted a compliance plan on July 30, 2026 and is awaiting Nasdaq review; Nasdaq may grant an extension of up to 180 days, but delisting remains possible.
- Legal and Contractual Cash Claims
- A former-employee lawsuit was settled on July 15, 2026 for $425,000, while a separate Redwood City lease dispute involves approximately $0.7 million of unpaid rent plus potential damages and attorney’s fees. The Company also reported $5.827 million of contingent consideration, including a $1.000 million milestone it was unable to pay by the contractual due date because of limited cash.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.18
- Segment
- Biotechnology: $0 revenue for the three and six months ended June 30, 2026; the Company operates as a single segment. Six-month R&D expense was $1.743 million and G&A expense was $2.180 million.
What they said about what is next.
No quantitative revenue or EPS guidance was provided. Management expects significant expenses and negative cash flows for the foreseeable future, states that current liquidity may not fund operations for the next 12 months, and expects to seek additional financing primarily through equity offerings.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 29, 2026
- XCUR's Q1 2026 10-Q filing reveals a continuing trend of financial difficulties, with total revenue remaining at $0, a significant net loss of $1.8 million, and a decrease in operating expenses. The company's liquidity…
- 10-K · March 25, 2026
- Exicure has transitioned from an R&D biotech to a shell pursuing strategic alternatives after selling its historical IP; as of December 31, 2025 it reported cash and cash equivalents of approximately $3.7 million and…
- 10-Q · November 7, 2025
- Exicure reported no revenue for Q3 2025 and a net loss of $2,437,000 (diluted loss per share $(0.39)). Cash and cash equivalents declined to $4,438,000 as of September 30, 2025 from $12,508,000 at December 31, 2024. The…
- 10-Q · June 27, 2025
- Exicure reported net income of $3,010 (in thousands) or $0.49 diluted EPS for the quarter ended March 31, 2025, driven primarily by non‑operational items (a $5,974 gain on early lease termination and $191 gain on…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing XCUR makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever